Latest News

Roche gets FDA priority review for atezolizumab

PD-L1 (programmed death-ligand 1), which is expressed on tumour cells and tumour-infiltrating immune cells, interacts with PD-1 and B7.1, both found on the surface of T cells, causing inhibition of T cells. By blocking this interaction, atezolizumab can trigger activation of T cells, restoring their ability to effectively detect and attack tumour cells. © Genentech


by tg

Roche is expanding its indications in cancer immunotherapy. Following FDA approvals of its PD-L1 checkpoint inhibitor atezolizumab in NSCLC and bladder cancer patients refractive to platinum-based chemotherapy, the Swiss pharma major is awaiting a FDA decision on whether the antibody is suitable as first-line treatment in a further subpopulation of bladder cancer patients.

Based on results of a single arm Phase II study, the FDA granted atezolizumab Priority Review in an additional type of advanced bladder cancer. While the agency granted accelerated market approval in May 2016 for the anti-PD-L1 antibody in patients who were treatment-refractive to platinum-based chemotherapy in neoadjuvant or adjuvant setting, the current priority review extends treatment options. Until April 2017, the agency will decide on the approval of atezolizumab in patients with bladder cancer not eligible for cisplatin chemotherapy (first-line treatment) or disease progression after 12 months of cisplatin therapy before or after surgery.

Roche’s supplemental biologics license application (sBLA) submission for atezolizumab is based on results from the Phase II IMvigor210 study. IMvigor210 is an open-label, single-arm Phase II study that evaluated the safety and efficacy of atezolizumab in people with locally advanced or metastatic bladder cancer, regardless of PD-L1 expression. The primary endpoint of the study was objective response rate (ORR). Secondary endpoints included duration of response (DOR), overall survival (OS), progression-free survival (PFS) and safety.

First drug found to reduce COVID-19-mortality

According to Principal Investigator Peter Horby from the University of Oxford, the cheap immunomodulatory drug dexamethasone helped reducing...

Cevec launches ELEVECTA platform

At the time of Cevec Pharmaceuticals’s announcement, US researchers reported that AAV gene therapy might be the most promising way to bridge the...

COVID-19: Siemens’ assay outperforms antibody tests from competitors

For Germany’s government, it is bad news: to establish immunity passports aimed at identifying people who have developed antibodies against...

New insulin fomulation allows faster blood sugar management

A new, ultra-rapid formulation of insulin reached peak activity in pigs with diabetes about twice as fast as a commercially available option,...

VarmX bags €32m in Series B round

New investors LSP, Ysios Capital, INKEF Capital and Lundbeckfonden Ventures joined the financing round, with the contribution of existing investors...

Artes enters COVID-19 vaccine race

Recombinant vaccine contract manufacurer ARTES Biotechnology GmbH has entered development of a SARS-CoV-2 vaccine based on its virus-like particle...

SARS-CoV2 antibody tests: not suited for individual diagnosis?

This is no good message for policymakers willing to relax social distancing measures based on immunity passports or antibody titers against the...